Navigation Links
Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
Date:1/7/2008

SAN FRANCISCO, Jan. 7 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced an update on the company's HCV pipeline, including promising second-generation polymerase and protease inhibitor compounds for the treatment of hepatitis C. This update will be presented on Tuesday, January 8, at 2:30 p.m. PT at the JP Morgan Healthcare Conference in San Francisco, CA.

Second-Generation Nucleoside Polymerase Inhibitor Program

Idenix's preclinical HCV nucleoside polymerase inhibitor program comprises two novel nucleotide prodrugs, IDX184 and IDX102. This program is based on Idenix's proprietary liver-targeting technology, which delivers high levels of nucleoside triphosphate in the liver, potentially maximizing drug efficacy and limiting systemic side effects.

In preclinical studies using an HCV replicon assay, IDX184 exhibited 10 times greater potency than nucleosides currently in clinical development. In a 7-day preclinical toxicology study of IDX184, no toxicities, including gastrointestinal or hematological, were observed in monkeys at doses greater than or equal to 600 mg/kg/day. In HCV genotype-1 infected chimpanzees, once- daily oral administration of 10 mg/kg of either nucleotide prodrug produced a rapid and potent inhibition of HCV replication with mean viral load reductions ranging from 1.5 log(10) with IDX102 to 2.5-4.0 log(10) with IDX184 after 4 days of dosing. IDX184 has been selected as the company's lead candidate from this program and clinical data are expected in 2008.

Novel Macrocyclic Protease Inhibitor Program

Idenix is e
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
4. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
11. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015  Attorney Advertising-- Bronstein, Gewirtz ... behalf of purchasers of the securities of AMAG ... -News).  Such investors are advised to contact ... Eitan Kimelman at info@bgandg.com ... AMAG and certain of its officers and/or directors ...
(Date:7/27/2015)... , July 27, 2015 As per ... Market - Global Industry Analysis, Size, Share, Growth, Trends and ... USD 7.96 billion in 2014, growing at a CAGR of ... billion in 2021. The global bionics market is ... accidents, which is leading to paralysis or amputation of body ...
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) has ... Market - Global Industry Analysis, Size, Share, Volume, ... report to their offering. At ... of the fastest growing markets globally. This remarkable ... care awareness, preference of the people for preventive ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3
... , WESTON, Fla., ... Company") is pleased to announce that they have opened a regional ... been able to secure a location abroad, providing an essential gateway ... safety products for children and adults to be distributed and sold ...
... , BEDFORD, Mass., Nov. 25 Hologic, Inc. (Hologic or ... and supplier of premium diagnostics, medical imaging systems and surgical ... using the annual meeting of the Radiological Society of North ... December 3, 2009 to highlight our new SecurView(®) DX multimodality ...
Cached Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4
(Date:7/27/2015)... ... July 28, 2015 , ... ... Skills and Innovative Techniques to Improve the Quality of Investigations , **Presented by ... , Inadequate investigations and CAPAs have been the #1 reason for 483 observations ...
(Date:7/27/2015)... ... July 27, 2015 , ... Specific cardiovascular risk ... regional brain volumes that may be early indicators of Alzheimer’s disease and dementia, ... know that vascular risk factors damage the brain and can result in cognitive ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association of ... its VIP Woman of the Year Circle. She is recognized with this prestigious distinction ... women, boasting more than 700,000 members and over 200 operating Local Chapters. , “I’m ...
(Date:7/27/2015)... , ... July 28, 2015 , ... ... Gilda Baum- Lappe as a 2015 Professional Woman of the Year. Ms. ... largest, most-recognized networking organization of professional women in the country, spanning virtually every ...
(Date:7/27/2015)... ... 27, 2015 , ... The heroin epidemic is affecting the Charlotte in North ... 7th. The rate for heroin usage has continued to climb around the country in ... less expensive alternative for those with an addiction to prescription opiate medications. According to ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 4Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 3Health News:NAPW Inducts Joanne Saniewski, Principal of the Frontier School District's Big Tree Elementary, Into its VIP Woman of the Year Circle 2Health News:NAPW Inducts Gilda Baum-Lappe, Journalist / Correspondent of Hollywood Foreign Press Association Into its VIP Woman of the Year Circle 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3
... cite proprietary research, strategic planning and ... superior creative as keys to their success, INDIANAPOLIS, Jan. ... awards at the Consumer Health World Conference in,Chicago this fall, ... top honors in a national awards program., The Service ...
... Minority and low-income patients are less likely than those ... to post-surgery epidural pain relief, according to new research ... Medicine. The study, published recently in the journal Anesthesia ... may influence health care choices when access to care ...
... Institute for Brain Research will head an ambitious new ... supported by a $8.5M grant from the Ellison Medical ... are prominent experts in neuroimaging and human brain development. ... first appear in early childhood. Autism impairs social interactions ...
... Calif., Jan. 31 BioForm Medical,Inc. (Nasdaq: BFRM ) ... 2007, which is the Company,s second quarter of fiscal,year 2008. ... 31,2007 as compared to $11.8 million for the quarter ended ... net loss was $1.6 million for the,quarter ended December 31, ...
... Inc. (OTC Bulletin Board: ACPH) is pleased to ... Company,s application to,list its common stock on the ... commence trading on NASDAQ on February 4, 2008,under ... to join the growing list of specialty pharmaceutical,companies ...
... D Seniors Also Enjoy Broad Choice of,Prescription Drugs, ... issued the following statement on new budget,figures that report ... over the,next ten years than was estimated last summer:, ... beneficiaries,choice of prescription drugs. New budget documents show that ...
Cached Medicine News:Health News:St.Vincent and Publicis Indianapolis Receive National Service Industry Advertising Awards 2Health News:St.Vincent and Publicis Indianapolis Receive National Service Industry Advertising Awards 3Health News:African-Americans less likely to choose epidurals for postoperative pain relief 2Health News:MIT's McGovern Institute researchers awarded $8.5M to study brain basis of autism and dyslexia 2Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 2Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 3Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 4Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 5Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 6Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 7Health News:Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: